“Advances in artificial intelligence tools rooted in rigorous biophysics represent a new frontier in drug discovery,” said David Wang, M.D., Ph.D., Senior Managing Director and Partner at OrbiMed, who will also join the company’s Board of Directors. “TandemAI has assembled an outstanding core team to leverage this opportunity with a vision for creating a new drug discovery engine that is based on accurate quantum mechanics, large scale experimental data, and artificial intelligence.”
TandemAI’s co-founders bring deep experience and exceptional track records in building, leading, and financing innovative drug discovery and development organizations. Mr. He has more than 20 years of experience in senior business leadership roles at companies, including most recently at HiFiBiO, where he served as co-founder and COO, and Harbour BioMed, where he was a co-founder and CFO. Wei Tang, Ph.D., TandemAI’s COO, was previously the CEO of Shanghai ChemPartner and a member of its board of directors. Before joining ChemPartner, he served at Merck in several senior research roles, with his latest position as a Distinguished Senior Investigator.
TandemAI is rapidly setting up state-of-the-art wet labs and high-performance computing clusters in China.